164 related articles for article (PubMed ID: 1478168)
1. [Adjuvant hormonal therapy in lymph node-negative breast carcinoma patients in the postmenopause].
Kurz C; Scholten C; Zielinski C; Czerwenka K; Kubista E; Spona J; Sevelda P
Dtsch Med Wochenschr; 1992 Dec; 117(51-52):1943-6. PubMed ID: 1478168
[TBL] [Abstract][Full Text] [Related]
2. [Clinical analysis of resectable breast cancer: a report of 6 263 cases].
Yang MT; Rong TH; Huang ZF; Zeng CG; Long H; Fu JH; Lin P; Wang X; Wang SY; Wang X; Tang J
Ai Zheng; 2005 Mar; 24(3):327-31. PubMed ID: 15757535
[TBL] [Abstract][Full Text] [Related]
3. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
Kennecke H; McArthur H; Olivotto IA; Speers C; Bajdik C; Chia SK; Ellard S; Norris B; Hayes M; Barnett J; Gelmon KA
Cancer; 2008 Apr; 112(7):1437-44. PubMed ID: 18286526
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L
Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590
[TBL] [Abstract][Full Text] [Related]
5. Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93)--the German Adjuvant Breast Cancer Group.
Kaufmann M; Graf E; Jonat W; Eiermann W; Geberth M; Albert US; Gademann G; Conrad B; Stahl K; von Minckwitz G; Schumacher M;
J Clin Oncol; 2005 Nov; 23(31):7842-8. PubMed ID: 16258087
[TBL] [Abstract][Full Text] [Related]
6. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
[TBL] [Abstract][Full Text] [Related]
7. The effect of adjuvant tamoxifen: the latest results from the Cancer Research Campaign Adjuvant Breast Trial. Cancer Research Campaign Breast Cancer Trials Group.
Eur J Cancer; 1992; 28A(4-5):904-7. PubMed ID: 1524921
[TBL] [Abstract][Full Text] [Related]
8. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.
Morales L; Canney P; Dyczka J; Rutgers E; Coleman R; Cufer T; Welnicka-Jaskiewicz M; Nortier J; Bogaerts J; Therasse P; Paridaens R; ;
Eur J Cancer; 2007 Jan; 43(2):331-40. PubMed ID: 17134892
[TBL] [Abstract][Full Text] [Related]
9. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
Søiland H; Skaland I; Varhaug JE; Kørner H; Janssen EA; Gudlaugsson E; Baak JP; Søreide JA
Acta Oncol; 2009; 48(4):514-21. PubMed ID: 19107621
[TBL] [Abstract][Full Text] [Related]
10. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.
; Colleoni M; Gelber S; Goldhirsch A; Aebi S; Castiglione-Gertsch M; Price KN; Coates AS; Gelber RD
J Clin Oncol; 2006 Mar; 24(9):1332-41. PubMed ID: 16505417
[TBL] [Abstract][Full Text] [Related]
11. A randomized trial of long term adjuvant tamoxifen plus postoperative radiation therapy versus radiation therapy alone for patients with early stage breast carcinoma treated with breast-conserving surgery. Stockholm Breast Cancer Study Group.
Dalberg K; Johansson H; Johansson U; Rutqvist LE
Cancer; 1998 Jun; 82(11):2204-11. PubMed ID: 9610700
[TBL] [Abstract][Full Text] [Related]
12. Segmental mastectomy and tamoxifen alone provide adequate locoregional control of breast cancer in elderly women.
Yeh S; Tan LR; O'Connell TX
Am Surg; 1997 Oct; 63(10):854-7. PubMed ID: 9322656
[TBL] [Abstract][Full Text] [Related]
13. Isolate local failure after breast-conserving treatment for early breast cancer, about 57 cases.
Deniaud-Alexandre E; Lauratet B; Lefranc JP; Genestié C; Lerouge D; Moureau-Zabotto L; Touboul E
Cancer Radiother; 2004 Apr; 8(2):95-107. PubMed ID: 15063877
[TBL] [Abstract][Full Text] [Related]
14. Low risk of locoregional recurrence of primary breast carcinoma after treatment with a modification of the Halsted radical mastectomy and selective use of radiotherapy.
Bijker N; Rutgers EJ; Peterse JL; van Dongen JA; Hart AA; Borger JH; Kroon BB
Cancer; 1999 Apr; 85(8):1773-81. PubMed ID: 10223572
[TBL] [Abstract][Full Text] [Related]
15. Improving local control with breast-conserving therapy: a 27-year single-institution experience.
Cabioglu N; Hunt KK; Buchholz TA; Mirza N; Singletary SE; Kuerer HM; Babiera GV; Ames FC; Sahin AA; Meric-Bernstam F
Cancer; 2005 Jul; 104(1):20-9. PubMed ID: 15912514
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of lymph node metastases after neoadjuvant chemotherapy for large-sized operable carcinoma of the breast.
Botti C; Vici P; Lopez M; Scinto AF; Cognetti F; Cavaliere R
J Am Coll Surg; 1995 Sep; 181(3):202-8. PubMed ID: 7670678
[TBL] [Abstract][Full Text] [Related]
17. [A randomized clinical trial of adjuvant endocrine therapy after breast conserving surgery for early breast cancer. Cooperative Study Group for Breast Conserving Therapy].
Nakamura Y; Tominaga T; Nomura Y; Koyama H; Miura S; Morimoto T
Gan To Kagaku Ryoho; 1994 Jun; 21 Suppl 2():217-25. PubMed ID: 8037485
[TBL] [Abstract][Full Text] [Related]
18. Influence of the time between surgery and radiotherapy on local recurrence in patients with lymph node-positive, early-stage, invasive breast carcinoma undergoing breast-conserving surgery: results of the French Adjuvant Study Group.
Benchalal M; Le Prisé E; de Lafontan B; Berton-Rigaud D; Belkacemi Y; Romestaing P; Peignaux K; Courdi A; Monnier A; Montcuquet P; Goudier MJ; Marchal C; Chollet P; Abadie-Lacourtoisie S; Datchary J; Veyret C; Kerbrat P
Cancer; 2005 Jul; 104(2):240-50. PubMed ID: 15948160
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S
Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
